Abstract:BACKGROUND:Real-world evidence lacks for clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer (advNS-NSCLC) in Chinese patients.METHODS:Patients receiving first-line chemotherapy for advNS-NSCLC in four Chinese tertiary care hospitals from 2007 to 2012 were retrospectively identified for chart review. Propensity score methods created best matched pairs for platinum/pemetrexed versus other platinum-based doublets for head-to-head comparisons of early treatment discontinuation (completed treatment cycles <4), treatment failure (progressive disease or early treatment discontinuation), and adverse events (AE). Conventional multiple logistic regression analyses were also performed to confirm the impact of the studied platinum-based doublets on early treatment discontinuation, treatment failure, and hematological AE using vinorelbine/platinum as reference.RESULTS:1,846 patients were included to create propensity score matched treatment groups for platinum/pemetrexed versus docetaxel (95 pairs), paclitaxel (118 pairs), gemcitabine (199 pairs), and vinorelbine (72 pairs)-contained doublet, respectively. Platinum/pemetrexed was associated with significantly lower risks of early treatment discontinuation (odds ratio (OR) ranged from 0.239, p = 0.001 relative to platinum/docetaxel to 0.389, p = 0.003 relative to platinum/paclitaxel) and treatment failure (OR ranged from 0.257, p < 0.001 relative to platinum/paclitaxel to 0.381, p < 0.001 relative to platinum/gemcitabine) than the other four studied doublets. Platinum/pemetrexed was also associated with several significantly lower hematological AE rates, such as versus platinum/paclitaxel (any hematological AE: OR 0.508, p = 0.032), platinum/gemcitabine (i.e., any hematological AE: OR 0.383, p < 0.001; anemia: OR 0.357, p < 0.001; thrombocytopenia: OR 0.345, p < 0.001) or platinum/vinorelbine (i.e., neutropenia: OR 0.360, p = 0.046; anemia: OR 0.181, p = 0.014) in matched patients. Further conventional logistic regression analyses indicated that pemetrexed/platinum was ranked lowest for the risks of early treatment discontinuation (OR 0.326, p < 0.001), treatment failure (OR 0.460, p < 0.001), and any hematological AE (OR 0.329, p < 0.001).CONCLUSIONS:Pemetrexed plus platinum had significantly superior clinical effectiveness as compared to the other platinum-based doublets with third-generation cytotoxic agents and was also associated with several lower hematological toxicity rates than gemcitabine or vinorelbine-based doublet in the first-line setting for advNS-NSCLC in Chinese patients.

Effect of Pemetrexed Plus Platinum for Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

The Pemetrexed-Containing Treatments in the Non-small Cell Lung Cancer, is -/Low Thymidylate Synthase Expression Better Than +/high Thymidylate Synthase Expression? A Meta-analysis

The Efficacy of Pemetrexed Combined Cis-platinum Chemotherapy for Patients with Advanced Non Small Cell Lung Cancer and the Effect on Serum Tumor Markers

Clinical observation of efficacy and safety of pemetrexed plus platinum as the first-line chemotherapy with advanced non-squamous non-small cell lung cancer

Clinical Observation of Pemetrexed Monotherapy or in Combination with Platinum As Second-Line Treatment to Advanced Non-Squamous Non-Small Cell Lung Cancer

Pemetrexed plus platinum in non-small cell lung cancer:a Meta analysis of randomized controlled trials

[Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Prognostic Prediction of Pemetrexed-Platinum Chemotherapeutic Regimen for NSCLC by Serum Metabolomics.

Pemetrexed Monotherapy Versus Pemetrexed Plus Platinum Combination As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

Pemetrexed Versus Docetaxel to Modulate Immune Environment in NSCLC Patients

Pemetrexed As the First-Line Therapy for Chinese Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer.

Pemetrexed Combined with Platinum As First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Brain Metastasis

Clinical Effectiveness and Clinical Toxicity Associated with Platinum-Based Doublets in the First-Line Setting for Advanced Non-Squamous Non-Small Cell Lung Cancer in Chinese Patients: a Retrospective Cohort Study.

Clinical Study of Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer

Full-dose Pemetrexed Plus Cisplatin Combined with Concurrent Thoracic Radiotherapy for Previously Untreated Advanced Nonsquamous Non-Small Cell Lung Cancer.

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma

Tumor Response and Clinical Toxicity Associated with Second‐line Chemotherapy Regimens for Advanced Non‐squamous Non‐small Cell Lung Cancer: A Retrospective Cohort Study